Case number | Time of onset of ICI | ICI agent (clinical trial or RC) | Events between onset of ICI and IP | Time of IP onset | Time of IP onset after beginning of ICI months | IP severity grade according to CTCAE 4.0 | Symptoms | Diagnostic method | ICI interruption or discontinuation | Steroid treatment | IP outcome |
1 | April 2015 | P (RC) | Concurrent Pseudomonas aeruginosa pneumonia | June 2017 | 26 | 4 | Respiratory failure | BAL | Discontinued June 2017 | Yes | Death after initial clinical and radiological improvement |
2 | Aug 2016 | N (clinical trial) | Cryotherapy of the chest wall metastasis | Oct 2017 | 13 | 3 | Dyspnoea | Response to therapy | Discontinued Sept 2017 | Yes | Clinical and radiological improvement |
3 | July 2016 | I+N then N (RC) | No | April 2017 | 9 | 1 | None | Histology (surgical excision) | No | No | Clinical and radiological improvement |
4 | Dec 2016 | I+N then N (RC) | No | March 2017 | 3 | 3 | Dyspnoea, cough | BAL | Discontinued March 2017 | Yes | Clinical and radiological improvement |
5 | July 2016 | I+N then N (RC) | No | Dec 2016 | 5 | 1 | None | BAL | Discontinued Dec 2016 | No | Clinical and radiological improvement |
6 | Nov 2016 | N (RC) | No | Feb 2017 | 2 | 3 | Dyspnoea | Response to therapy | Discontinued Feb 2017 | Yes | Clinical and radiological improvement |
7 | April 2016 | D+T (clinical trial) | No | June 2016 | 2 | 3 | Dyspnoea, cough | BAL | Discontinued June 2016 | Yes | Clinical and radiological improvement |
8 | June 2016 | N (RC) | No | July 2017 | 13 | 1 | None | BAL | Discontinued June 2017 | Yes | Clinical and radiological improvement |
9 | May 2015 | I (clinical trial) | No | Sept 2015 | 4 | 1 | None | BAL and histology | Discontinued June 2017 | Yes | Clinical and radiological improvement |
10 | Oct 2015 | N (RC) | No | July 2016 | 8 | 4 | Dyspnoea | BAL | Discontinued July 2016 | Yes | Clinical and radiological improvement |
11 | Aug 2016 | I+N (RC) | No | Oct 2016 | 2 | 1 | None | Histology | Discontinued Oct 2016 | Yes | Clinical and radiological improvement |
12 | March 2017 | P (clinical trial) | No | Sept 2017 | 6 | 1 | Dyspnoea, cough | BAL | No | No | Slowed progression |
13 | Sept 2016 | N (RC) | Unproven superimposed infection of the RUL | Feb 2017 | 5 | 3 | Dyspnoea | BAL | Discontinued Feb 2017 | Yes | Clinical and radiological improvement |
14 | Sept 2010 | I (RC) | No | Oct 2010 | 1 | 3 | Cough | BAL | Discontinued Oct 2010 | Yes | Clinical and radiological improvement |
15 | Aug 2016 | N (RC) | RT | Feb 2018 | 17 | 3 | Dyspnoea | BAL | Discontinued Jan 2018 | Yes | Clinical and radiological improvement |
ICI: immune checkpoint inhibitors; RC: routine care; IP: immune-related pneumonitis; CTCAE: Common Terminology Criteria for Adverse Events; P: pembrolizumab; N: nivolumab; I: ipilimumab; D: durvalumab; T: tremelimumab; RUL: right upper lobe; RT: radiotherapy; BAL: bronchoalveolar lavage.